BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29580198)

  • 1. Pharmacogenetics of oral antidiabetic therapy.
    Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
    Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of oral antidiabetic treatment.
    Schroner Z; Javorsky M; Kozarova M; Tkac I
    Bratisl Lek Listy; 2011; 112(8):441-6. PubMed ID: 21863614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
    Emami-Riedmaier A; Schaeffeler E; Nies AT; Mörike K; Schwab M
    J Intern Med; 2015 Feb; 277(2):235-247. PubMed ID: 25418285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015.
    Lunger L; Melmer A; Oberaigner W; Leo M; Juchum M; Pölzl K; Gänzer J; Innerebner M; Eisendle E; Beck G; Kathrein H; Heindl B; Schönherr HR; Lechleitner M; Tilg H; Ebenbichler C
    Wien Klin Wochenschr; 2017 Jan; 129(1-2):46-51. PubMed ID: 27909794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes.
    Damanhouri ZA; Alkreathy HM; Alharbi FA; Abualhamail H; Ahmad MS
    Int J Med Sci; 2023; 20(1):142-150. PubMed ID: 36619226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus.
    Jermendy G; Wittmann I; Nagy L; Kiss Z; Rokszin G; Abonyi-Tóth Z; Katona L; Paragh G; Karádi I; Merkely B
    Med Sci Monit; 2012 Feb; 18(2):CR72-77. PubMed ID: 22293880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and personalized treatment of type 2 diabetes.
    Semiz S; Dujic T; Causevic A
    Biochem Med (Zagreb); 2013; 23(2):154-71. PubMed ID: 23894862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pitfalls and precautions concerning the use of conventional oral antidiabetic drugs].
    Scheen AJ
    Rev Med Liege; 2002 May; 57(5):352-6. PubMed ID: 12143186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of Antidiabetic Drugs.
    Srinivasan S; Yee SW; Giacomini KM
    Adv Pharmacol; 2018; 83():361-389. PubMed ID: 29801583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
    Goodarzi MO; Bryer-Ash M
    Diabetes Obes Metab; 2005 Nov; 7(6):654-65. PubMed ID: 16219009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
    Manolopoulos VG; Ragia G; Tavridou A
    Pharmacogenomics; 2011 Aug; 12(8):1161-91. PubMed ID: 21843065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics of oral antidiabetic treatment].
    Tkáč I
    Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral hypoglycemic agents and metformin in the treatment of type II non-insulin-dependent diabetes].
    Isnard F
    Sem Hop; 1983 Dec; 59(49):3437-8. PubMed ID: 6320423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin pharmacogenomics: current status and future directions.
    Pawlyk AC; Giacomini KM; McKeon C; Shuldiner AR; Florez JC
    Diabetes; 2014 Aug; 63(8):2590-9. PubMed ID: 25060887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics of type 2 diabetes mellitus and other specific types of diabetes; its role in treatment modalities.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(1):54-8. PubMed ID: 23014256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study.
    Liu CH; Chen ST; Chang CH; Chuang LM; Lai MS
    Public Health; 2017 Nov; 152():20-27. PubMed ID: 28719837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.